CA2868156A1 - Composes de pyridopyrimidine substituee et leur utilisation comme inhibiteurs de flt3 - Google Patents
Composes de pyridopyrimidine substituee et leur utilisation comme inhibiteurs de flt3 Download PDFInfo
- Publication number
- CA2868156A1 CA2868156A1 CA2868156A CA2868156A CA2868156A1 CA 2868156 A1 CA2868156 A1 CA 2868156A1 CA 2868156 A CA2868156 A CA 2868156A CA 2868156 A CA2868156 A CA 2868156A CA 2868156 A1 CA2868156 A1 CA 2868156A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- administration
- amino
- leukemia
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261614274P | 2012-03-22 | 2012-03-22 | |
US61/614,274 | 2012-03-22 | ||
PCT/US2013/032575 WO2013142382A1 (fr) | 2012-03-22 | 2013-03-15 | Composés de pyridopyrimidine substituée et leur utilisation comme inhibiteurs de flt3 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2868156A1 true CA2868156A1 (fr) | 2013-09-26 |
CA2868156C CA2868156C (fr) | 2020-07-28 |
Family
ID=49223277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2868156A Active CA2868156C (fr) | 2012-03-22 | 2013-03-15 | Composes de pyridopyrimidine substituee et leur utilisation comme inhibiteurs de flt3 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8877763B2 (fr) |
EP (1) | EP2828259B1 (fr) |
JP (1) | JP6101341B2 (fr) |
KR (1) | KR102011770B1 (fr) |
CN (1) | CN104428298B (fr) |
AU (1) | AU2013235344B2 (fr) |
BR (1) | BR112014023460B1 (fr) |
CA (1) | CA2868156C (fr) |
CL (1) | CL2014002505A1 (fr) |
EA (1) | EA031267B1 (fr) |
ES (1) | ES2694223T3 (fr) |
HK (1) | HK1208453A1 (fr) |
IL (1) | IL234802B (fr) |
IN (1) | IN2014MN02082A (fr) |
MX (1) | MX360912B (fr) |
MY (1) | MY184858A (fr) |
NZ (1) | NZ700283A (fr) |
PL (1) | PL2828259T3 (fr) |
SG (1) | SG11201405942RA (fr) |
TR (1) | TR201816480T4 (fr) |
WO (1) | WO2013142382A1 (fr) |
ZA (1) | ZA201407588B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102228034B1 (ko) * | 2013-10-21 | 2021-03-16 | 제노스코 | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 |
CN105272930B (zh) * | 2014-07-17 | 2018-07-13 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
EP3220914B1 (fr) | 2014-11-17 | 2020-09-02 | Rhode Island Hospital | Compositions de nanomatériau, synthèse et assemblage |
US20210275532A1 (en) * | 2018-06-27 | 2021-09-09 | Oscote Inc. | Pyridopyrimidinone derivatives for use as axl inhibitors |
KR20200022712A (ko) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법 |
KR102230721B1 (ko) * | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN110327347B (zh) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | G-749在制备抗真菌药物中的应用 |
TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
EP4054579A1 (fr) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
WO2023027966A1 (fr) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3 |
TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
WO2023225005A1 (fr) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Polythérapie à base de flt3 pour le cancer et compositions associées |
KR102440707B1 (ko) | 2022-07-10 | 2022-09-05 | 이우미 | 공장 추천 시스템 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2394525A1 (fr) * | 2000-01-27 | 2001-08-02 | Warner-Lambert Company | Derives de pyridopyrimidinone destines au traitement de maladies maladie neurodegenerative |
WO2002018379A2 (fr) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines |
CA2420286A1 (fr) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7 oxo pyridopyrimidines comme inhibiteurs d'une proliferation cellulaire |
EP2025678A1 (fr) * | 2007-08-17 | 2009-02-18 | Oncalis AG | Composés pyrazolo[3,4-d]pyrimidine et leur utilisation comme modulateur de protein kinase |
TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
EP2330909B1 (fr) * | 2008-08-12 | 2013-09-18 | GlaxoSmithKline LLC | Composés chimiques |
US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
EP2467137A1 (fr) * | 2009-08-19 | 2012-06-27 | Ambit Biosciences Corporation | Composés biaryles et procédés d utilisation de ceux-ci |
TR201802464T4 (tr) * | 2009-10-29 | 2018-03-21 | Genosco | Ki̇naz i̇nhi̇bi̇törleri̇ |
-
2013
- 2013-03-15 EA EA201491747A patent/EA031267B1/ru not_active IP Right Cessation
- 2013-03-15 CN CN201380025782.8A patent/CN104428298B/zh active Active
- 2013-03-15 US US13/841,827 patent/US8877763B2/en active Active
- 2013-03-15 SG SG11201405942RA patent/SG11201405942RA/en unknown
- 2013-03-15 PL PL13763998T patent/PL2828259T3/pl unknown
- 2013-03-15 WO PCT/US2013/032575 patent/WO2013142382A1/fr active Application Filing
- 2013-03-15 NZ NZ700283A patent/NZ700283A/en unknown
- 2013-03-15 MX MX2014011354A patent/MX360912B/es active IP Right Grant
- 2013-03-15 ES ES13763998.5T patent/ES2694223T3/es active Active
- 2013-03-15 IN IN2082MUN2014 patent/IN2014MN02082A/en unknown
- 2013-03-15 CA CA2868156A patent/CA2868156C/fr active Active
- 2013-03-15 KR KR1020147029509A patent/KR102011770B1/ko active IP Right Grant
- 2013-03-15 BR BR112014023460-4A patent/BR112014023460B1/pt active IP Right Grant
- 2013-03-15 JP JP2015501823A patent/JP6101341B2/ja active Active
- 2013-03-15 TR TR2018/16480T patent/TR201816480T4/tr unknown
- 2013-03-15 MY MYPI2014702705A patent/MY184858A/en unknown
- 2013-03-15 EP EP13763998.5A patent/EP2828259B1/fr active Active
- 2013-03-15 AU AU2013235344A patent/AU2013235344B2/en active Active
-
2014
- 2014-09-22 IL IL234802A patent/IL234802B/en active IP Right Grant
- 2014-09-22 CL CL2014002505A patent/CL2014002505A1/es unknown
- 2014-10-20 ZA ZA2014/07588A patent/ZA201407588B/en unknown
-
2015
- 2015-09-16 HK HK15109075.2A patent/HK1208453A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CL2014002505A1 (es) | 2015-10-02 |
NZ700283A (en) | 2016-08-26 |
MX2014011354A (es) | 2014-12-05 |
AU2013235344B2 (en) | 2017-03-16 |
KR102011770B1 (ko) | 2019-08-19 |
US20130274274A1 (en) | 2013-10-17 |
PL2828259T3 (pl) | 2019-02-28 |
MX360912B (es) | 2018-11-22 |
EP2828259A4 (fr) | 2015-08-19 |
EA201491747A1 (ru) | 2015-10-30 |
ES2694223T3 (es) | 2018-12-19 |
IL234802B (en) | 2018-10-31 |
KR20140144709A (ko) | 2014-12-19 |
CN104428298B (zh) | 2017-03-01 |
TR201816480T4 (tr) | 2018-11-21 |
CN104428298A (zh) | 2015-03-18 |
SG11201405942RA (en) | 2014-10-30 |
BR112014023460B1 (pt) | 2020-09-01 |
JP6101341B2 (ja) | 2017-03-22 |
EA031267B1 (ru) | 2018-12-28 |
EP2828259B1 (fr) | 2018-08-08 |
MY184858A (en) | 2021-04-27 |
US8877763B2 (en) | 2014-11-04 |
ZA201407588B (en) | 2015-11-25 |
AU2013235344A1 (en) | 2014-10-09 |
EP2828259A1 (fr) | 2015-01-28 |
HK1208453A1 (en) | 2016-03-04 |
CA2868156C (fr) | 2020-07-28 |
JP2015510942A (ja) | 2015-04-13 |
IN2014MN02082A (fr) | 2015-08-21 |
WO2013142382A1 (fr) | 2013-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013235344B2 (en) | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors | |
US8404677B2 (en) | Kinase inhibitors | |
US20210238196A1 (en) | Spiro aromatic ring compound and application thereof | |
EP2498607B1 (fr) | Inhibiteurs de kinases | |
JP6035423B2 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
AU2014309788B2 (en) | Novel quinoline-substituted compound | |
CN110662536B (zh) | 激酶网络抑制剂及其用途 | |
WO2014113191A1 (fr) | Inhibiteurs de la voie signalisation hedgehog et leurs applications thérapeutiques | |
JP2022526854A (ja) | ホスファチジルイノシトール3-キナーゼ阻害剤 | |
JP7216105B2 (ja) | Erkキナーゼ阻害活性を有する化合物及びその使用 | |
KR20210014212A (ko) | Axl 억제제로 사용하기 위한 피리도피리미디논 유도체 | |
AU2010313240B2 (en) | Kinase inhibitors | |
WO2023169170A1 (fr) | Composé hétérocyclique utilisé en tant qu'inhibiteur de shp2, composition comprenant un composé hétérocyclique, et procédé l'utilisant | |
EP4342895A1 (fr) | Composé dérivé d'hétéroaryle et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20171212 |